 | • レポートコード：MRC2-11QY04370 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、93ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は原発性線毛機能不全のグローバル市場について調査・分析したレポートです。種類別（薬物治療、放射線療法、化学療法）市場規模、用途別（病院・診療所、研究センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別原発性線毛機能不全の競争状況、市場シェア ・世界の原発性線毛機能不全市場：種類別市場規模 2015年-2020年（薬物治療、放射線療法、化学療法） ・世界の原発性線毛機能不全市場：種類別市場規模予測 2021年-2026年（薬物治療、放射線療法、化学療法） ・世界の原発性線毛機能不全市場：用途別市場規模 2015年-2020年（病院・診療所、研究センター） ・世界の原発性線毛機能不全市場：用途別市場規模予測 2021年-2026年（病院・診療所、研究センター） ・北米の原発性線毛機能不全市場分析：米国、カナダ ・ヨーロッパの原発性線毛機能不全市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの原発性線毛機能不全市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の原発性線毛機能不全市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの原発性線毛機能不全市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AstraZeneca、Boehringer Ingelheim、Novartis、Teva、Bayer、Rotech Healthcare、Pfizer ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Primary ciliary dyskinesia (PCD), also called immotile ciliary syndrome or Kartagener syndrome, is a rare, ciliopathic, autosomal recessive genetic disorder that causes defects in the action of cilia lining the respiratory tract (lower and upper, sinuses, Eustachian tube, middle ear), fallopian tube, and flagella of sperm cells.
There no standardized effective treatment strategies for the condition. Severe fatal respiratory failure can develop; long-term treatment with macrolides such as clarithromycin, erythromycin and azithromycin has been empirically applied for the treatment of primary ciliary dyskinesia in Japan, though controversial due to the effects of the medications.
Market Analysis and Insights: Global Primary Ciliary Dyskinesia Market
The global Primary Ciliary Dyskinesia market size is projected to reach US$ 443.1 million by 2026, from US$ 418.8 million in 2020, at a CAGR of 5.4%% during 2021-2026.
Global Primary Ciliary Dyskinesia Scope and Market Size
Primary Ciliary Dyskinesia market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Primary Ciliary Dyskinesia market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
AstraZeneca
Boehringer Ingelheim
Novartis
Teva
Bayer
Rotech Healthcare
Pfizer
…
Market segment by Type, the product can be split into
Drug Treatment
Radiotherapy
Chemotherapy
Market segment by Application, split into
Hospitals & Clinics
Research Centers
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Primary Ciliary Dyskinesia Revenue
1.4 Market by Type
1.4.1 Global Primary Ciliary Dyskinesia Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Drug Treatment
1.4.3 Radiotherapy
1.4.4 Chemotherapy
1.5 Market by Application
1.5.1 Global Primary Ciliary Dyskinesia Market Share by Application: 2020 VS 2026
1.5.2 Hospitals & Clinics
1.5.3 Research Centers
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Primary Ciliary Dyskinesia Market Perspective (2015-2026)
2.2 Global Primary Ciliary Dyskinesia Growth Trends by Regions
2.2.1 Primary Ciliary Dyskinesia Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Primary Ciliary Dyskinesia Historic Market Share by Regions (2015-2020)
2.2.3 Primary Ciliary Dyskinesia Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Primary Ciliary Dyskinesia Market Growth Strategy
2.3.6 Primary Interviews with Key Primary Ciliary Dyskinesia Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Primary Ciliary Dyskinesia Players by Market Size
3.1.1 Global Top Primary Ciliary Dyskinesia Players by Revenue (2015-2020)
3.1.2 Global Primary Ciliary Dyskinesia Revenue Market Share by Players (2015-2020)
3.1.3 Global Primary Ciliary Dyskinesia Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Primary Ciliary Dyskinesia Market Concentration Ratio
3.2.1 Global Primary Ciliary Dyskinesia Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Primary Ciliary Dyskinesia Revenue in 2019
3.3 Primary Ciliary Dyskinesia Key Players Head office and Area Served
3.4 Key Players Primary Ciliary Dyskinesia Product Solution and Service
3.5 Date of Enter into Primary Ciliary Dyskinesia Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Primary Ciliary Dyskinesia Historic Market Size by Type (2015-2020)
4.2 Global Primary Ciliary Dyskinesia Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Primary Ciliary Dyskinesia Market Size by Application (2015-2020)
5.2 Global Primary Ciliary Dyskinesia Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Primary Ciliary Dyskinesia Market Size (2015-2020)
6.2 Primary Ciliary Dyskinesia Key Players in North America (2019-2020)
6.3 North America Primary Ciliary Dyskinesia Market Size by Type (2015-2020)
6.4 North America Primary Ciliary Dyskinesia Market Size by Application (2015-2020)
7 Europe
7.1 Europe Primary Ciliary Dyskinesia Market Size (2015-2020)
7.2 Primary Ciliary Dyskinesia Key Players in Europe (2019-2020)
7.3 Europe Primary Ciliary Dyskinesia Market Size by Type (2015-2020)
7.4 Europe Primary Ciliary Dyskinesia Market Size by Application (2015-2020)
8 China
8.1 China Primary Ciliary Dyskinesia Market Size (2015-2020)
8.2 Primary Ciliary Dyskinesia Key Players in China (2019-2020)
8.3 China Primary Ciliary Dyskinesia Market Size by Type (2015-2020)
8.4 China Primary Ciliary Dyskinesia Market Size by Application (2015-2020)
9 Japan
9.1 Japan Primary Ciliary Dyskinesia Market Size (2015-2020)
9.2 Primary Ciliary Dyskinesia Key Players in Japan (2019-2020)
9.3 Japan Primary Ciliary Dyskinesia Market Size by Type (2015-2020)
9.4 Japan Primary Ciliary Dyskinesia Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Primary Ciliary Dyskinesia Market Size (2015-2020)
10.2 Primary Ciliary Dyskinesia Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Primary Ciliary Dyskinesia Market Size by Type (2015-2020)
10.4 Southeast Asia Primary Ciliary Dyskinesia Market Size by Application (2015-2020)
11 India
11.1 India Primary Ciliary Dyskinesia Market Size (2015-2020)
11.2 Primary Ciliary Dyskinesia Key Players in India (2019-2020)
11.3 India Primary Ciliary Dyskinesia Market Size by Type (2015-2020)
11.4 India Primary Ciliary Dyskinesia Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Primary Ciliary Dyskinesia Market Size (2015-2020)
12.2 Primary Ciliary Dyskinesia Key Players in Central & South America (2019-2020)
12.3 Central & South America Primary Ciliary Dyskinesia Market Size by Type (2015-2020)
12.4 Central & South America Primary Ciliary Dyskinesia Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 AstraZeneca
13.1.1 AstraZeneca Company Details
13.1.2 AstraZeneca Business Overview
13.1.3 AstraZeneca Primary Ciliary Dyskinesia Introduction
13.1.4 AstraZeneca Revenue in Primary Ciliary Dyskinesia Business (2015-2020))
13.1.5 AstraZeneca Recent Development
13.2 Boehringer Ingelheim
13.2.1 Boehringer Ingelheim Company Details
13.2.2 Boehringer Ingelheim Business Overview
13.2.3 Boehringer Ingelheim Primary Ciliary Dyskinesia Introduction
13.2.4 Boehringer Ingelheim Revenue in Primary Ciliary Dyskinesia Business (2015-2020)
13.2.5 Boehringer Ingelheim Recent Development
13.3 Novartis
13.3.1 Novartis Company Details
13.3.2 Novartis Business Overview
13.3.3 Novartis Primary Ciliary Dyskinesia Introduction
13.3.4 Novartis Revenue in Primary Ciliary Dyskinesia Business (2015-2020)
13.3.5 Novartis Recent Development
13.4 Teva
13.4.1 Teva Company Details
13.4.2 Teva Business Overview
13.4.3 Teva Primary Ciliary Dyskinesia Introduction
13.4.4 Teva Revenue in Primary Ciliary Dyskinesia Business (2015-2020)
13.4.5 Teva Recent Development
13.5 Bayer
13.5.1 Bayer Company Details
13.5.2 Bayer Business Overview
13.5.3 Bayer Primary Ciliary Dyskinesia Introduction
13.5.4 Bayer Revenue in Primary Ciliary Dyskinesia Business (2015-2020)
13.5.5 Bayer Recent Development
13.6 Rotech Healthcare
13.6.1 Rotech Healthcare Company Details
13.6.2 Rotech Healthcare Business Overview
13.6.3 Rotech Healthcare Primary Ciliary Dyskinesia Introduction
13.6.4 Rotech Healthcare Revenue in Primary Ciliary Dyskinesia Business (2015-2020)
13.6.5 Rotech Healthcare Recent Development
13.7 Pfizer
13.7.1 Pfizer Company Details
13.7.2 Pfizer Business Overview
13.7.3 Pfizer Primary Ciliary Dyskinesia Introduction
13.7.4 Pfizer Revenue in Primary Ciliary Dyskinesia Business (2015-2020)
13.7.5 Pfizer Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Primary Ciliary Dyskinesia Key Market Segments
Table 2. Key Players Covered: Ranking by Primary Ciliary Dyskinesia Revenue
Table 3. Ranking of Global Top Primary Ciliary Dyskinesia Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Primary Ciliary Dyskinesia Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Drug Treatment
Table 6. Key Players of Radiotherapy
Table 7. Key Players of Chemotherapy
Table 8. Global Primary Ciliary Dyskinesia Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Primary Ciliary Dyskinesia Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Primary Ciliary Dyskinesia Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Primary Ciliary Dyskinesia Market Share by Regions (2015-2020)
Table 12. Global Primary Ciliary Dyskinesia Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Primary Ciliary Dyskinesia Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Primary Ciliary Dyskinesia Market Growth Strategy
Table 18. Main Points Interviewed from Key Primary Ciliary Dyskinesia Players
Table 19. Global Primary Ciliary Dyskinesia Revenue by Players (2015-2020) (Million US$)
Table 20. Global Primary Ciliary Dyskinesia Market Share by Players (2015-2020)
Table 21. Global Top Primary Ciliary Dyskinesia Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Primary Ciliary Dyskinesia as of 2019)
Table 22. Global Primary Ciliary Dyskinesia by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Primary Ciliary Dyskinesia Product Solution and Service
Table 25. Date of Enter into Primary Ciliary Dyskinesia Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Primary Ciliary Dyskinesia Market Size by Type (2015-2020) (Million US$)
Table 28. Global Primary Ciliary Dyskinesia Market Size Share by Type (2015-2020)
Table 29. Global Primary Ciliary Dyskinesia Revenue Market Share by Type (2021-2026)
Table 30. Global Primary Ciliary Dyskinesia Market Size Share by Application (2015-2020)
Table 31. Global Primary Ciliary Dyskinesia Market Size by Application (2015-2020) (Million US$)
Table 32. Global Primary Ciliary Dyskinesia Market Size Share by Application (2021-2026)
Table 33. North America Key Players Primary Ciliary Dyskinesia Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Primary Ciliary Dyskinesia Market Share (2019-2020)
Table 35. North America Primary Ciliary Dyskinesia Market Size by Type (2015-2020) (Million US$)
Table 36. North America Primary Ciliary Dyskinesia Market Share by Type (2015-2020)
Table 37. North America Primary Ciliary Dyskinesia Market Size by Application (2015-2020) (Million US$)
Table 38. North America Primary Ciliary Dyskinesia Market Share by Application (2015-2020)
Table 39. Europe Key Players Primary Ciliary Dyskinesia Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Primary Ciliary Dyskinesia Market Share (2019-2020)
Table 41. Europe Primary Ciliary Dyskinesia Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Primary Ciliary Dyskinesia Market Share by Type (2015-2020)
Table 43. Europe Primary Ciliary Dyskinesia Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Primary Ciliary Dyskinesia Market Share by Application (2015-2020)
Table 45. China Key Players Primary Ciliary Dyskinesia Revenue (2019-2020) (Million US$)
Table 46. China Key Players Primary Ciliary Dyskinesia Market Share (2019-2020)
Table 47. China Primary Ciliary Dyskinesia Market Size by Type (2015-2020) (Million US$)
Table 48. China Primary Ciliary Dyskinesia Market Share by Type (2015-2020)
Table 49. China Primary Ciliary Dyskinesia Market Size by Application (2015-2020) (Million US$)
Table 50. China Primary Ciliary Dyskinesia Market Share by Application (2015-2020)
Table 51. Japan Key Players Primary Ciliary Dyskinesia Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Primary Ciliary Dyskinesia Market Share (2019-2020)
Table 53. Japan Primary Ciliary Dyskinesia Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Primary Ciliary Dyskinesia Market Share by Type (2015-2020)
Table 55. Japan Primary Ciliary Dyskinesia Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Primary Ciliary Dyskinesia Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Primary Ciliary Dyskinesia Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Primary Ciliary Dyskinesia Market Share (2019-2020)
Table 59. Southeast Asia Primary Ciliary Dyskinesia Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Primary Ciliary Dyskinesia Market Share by Type (2015-2020)
Table 61. Southeast Asia Primary Ciliary Dyskinesia Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Primary Ciliary Dyskinesia Market Share by Application (2015-2020)
Table 63. India Key Players Primary Ciliary Dyskinesia Revenue (2019-2020) (Million US$)
Table 64. India Key Players Primary Ciliary Dyskinesia Market Share (2019-2020)
Table 65. India Primary Ciliary Dyskinesia Market Size by Type (2015-2020) (Million US$)
Table 66. India Primary Ciliary Dyskinesia Market Share by Type (2015-2020)
Table 67. India Primary Ciliary Dyskinesia Market Size by Application (2015-2020) (Million US$)
Table 68. India Primary Ciliary Dyskinesia Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Primary Ciliary Dyskinesia Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Primary Ciliary Dyskinesia Market Share (2019-2020)
Table 71. Central & South America Primary Ciliary Dyskinesia Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Primary Ciliary Dyskinesia Market Share by Type (2015-2020)
Table 73. Central & South America Primary Ciliary Dyskinesia Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Primary Ciliary Dyskinesia Market Share by Application (2015-2020)
Table 75. AstraZeneca Company Details
Table 76. AstraZeneca Business Overview
Table 77. AstraZeneca Product
Table 78. AstraZeneca Revenue in Primary Ciliary Dyskinesia Business (2015-2020) (Million US$)
Table 79. AstraZeneca Recent Development
Table 80. Boehringer Ingelheim Company Details
Table 81. Boehringer Ingelheim Business Overview
Table 82. Boehringer Ingelheim Product
Table 83. Boehringer Ingelheim Revenue in Primary Ciliary Dyskinesia Business (2015-2020) (Million US$)
Table 84. Boehringer Ingelheim Recent Development
Table 85. Novartis Company Details
Table 86. Novartis Business Overview
Table 87. Novartis Product
Table 88. Novartis Revenue in Primary Ciliary Dyskinesia Business (2015-2020) (Million US$)
Table 89. Novartis Recent Development
Table 90. Teva Company Details
Table 91. Teva Business Overview
Table 92. Teva Product
Table 93. Teva Revenue in Primary Ciliary Dyskinesia Business (2015-2020) (Million US$)
Table 94. Teva Recent Development
Table 95. Bayer Company Details
Table 96. Bayer Business Overview
Table 97. Bayer Product
Table 98. Bayer Revenue in Primary Ciliary Dyskinesia Business (2015-2020) (Million US$)
Table 99. Bayer Recent Development
Table 100. Rotech Healthcare Company Details
Table 101. Rotech Healthcare Business Overview
Table 102. Rotech Healthcare Product
Table 103. Rotech Healthcare Revenue in Primary Ciliary Dyskinesia Business (2015-2020) (Million US$)
Table 104. Rotech Healthcare Recent Development
Table 105. Pfizer Company Details
Table 106. Pfizer Business Overview
Table 107. Pfizer Product
Table 108. Pfizer Revenue in Primary Ciliary Dyskinesia Business (2015-2020) (Million US$)
Table 109. Pfizer Recent Development
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Primary Ciliary Dyskinesia Market Share by Type: 2020 VS 2026
Figure 2. Drug Treatment Features
Figure 3. Radiotherapy Features
Figure 4. Chemotherapy Features
Figure 5. Global Primary Ciliary Dyskinesia Market Share by Application: 2020 VS 2026
Figure 6. Hospitals & Clinics Case Studies
Figure 7. Research Centers Case Studies
Figure 8. Primary Ciliary Dyskinesia Report Years Considered
Figure 9. Global Primary Ciliary Dyskinesia Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Primary Ciliary Dyskinesia Market Share by Regions: 2020 VS 2026
Figure 11. Global Primary Ciliary Dyskinesia Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Primary Ciliary Dyskinesia Market Share by Players in 2019
Figure 14. Global Top Primary Ciliary Dyskinesia Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Primary Ciliary Dyskinesia as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Primary Ciliary Dyskinesia Revenue in 2019
Figure 16. North America Primary Ciliary Dyskinesia Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Primary Ciliary Dyskinesia Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Primary Ciliary Dyskinesia Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Primary Ciliary Dyskinesia Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Primary Ciliary Dyskinesia Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Primary Ciliary Dyskinesia Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Primary Ciliary Dyskinesia Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Bottom-up and Top-down Approaches for This Report
Figure 24. Data Triangulation
Figure 25. Key Executives Interviewed
遅発性ジスキネジアの世界市場（～2026年） Tardive Dyskinesia (TD) market is estimated to post significant growth in coming years, owing to rising schizophrenia patients, increasing bipolar patients, growing antipsychotic prescription and increasing incidence of neurological disorders. The key factors driving the growth of the Tardive dyskin…- 体外照射療法の世界市場（～2026年） Market Analysis and Insights: Global External Beam Radiotherapy Market The global External Beam Radiotherapy market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global External Beam Radiotherapy Scope and Market Size External Bea…
- 化学療法薬誘発性肢端紅斑（手足症候群）治療の世界市場（～2026年） Acral erythema, also called as hand-foot syndrome or palmar-plantar erythrodysesthesia, is characterized by swelling, redness, paraesthesia (numbness) and desquamation (skin peeling) of palms, soles and rarely on knees and elbow. Acryl erythema is an adverse drug reaction which typically appear afte…
- 画像誘導放射線治療（IGRT）の世界市場（～2026年） Image guided radiotherapy (IGRT), a type of conformal radiotherapy, involves the use of different scans and X-rays to treat an area of cancer. Conformal radiotherapy shape the radiotherapy beams around the area of the cancerous tissue. It uses X-rays and scans similar to CT scans before and during t…
- 化学療法誘発性貧血（CIA）の世界市場（～2026年） Anaemia is a frequent complication of malignancy and is aggravated by chemotherapy. The key factor contributing to the growth of the global chemotherapy induced anemia market is the increase in the occurrence of cancer and anemia among geriatric patients. Market Analysis and Insights: Global Chemoth…